468 related articles for article (PubMed ID: 31094083)
1. Skeletal muscle mass loss and dose-limiting toxicities in metastatic colorectal cancer patients.
Kurk S; Peeters P; Stellato R; Dorresteijn B; de Jong P; Jourdan M; Creemers GJ; Erdkamp F; de Jongh F; Kint P; Simkens L; Tanis B; Tjin-A-Ton M; Van Der Velden A; Punt C; Koopman M; May A
J Cachexia Sarcopenia Muscle; 2019 Aug; 10(4):803-813. PubMed ID: 31094083
[TBL] [Abstract][Full Text] [Related]
2. Loss of skeletal muscle index and survival in patients with metastatic colorectal cancer: Secondary analysis of the phase 3 CAIRO3 trial.
Kurk SA; Peeters PHM; Dorresteijn B; de Jong PA; Jourdan M; Creemers GM; Erdkamp FLG; de Jongh FE; Kint PAM; Poppema BJ; Radema SA; Simkens LHJ; Tanis BC; Tjin-A-Ton MLR; Van Der Velden A; Punt CJA; Koopman M; May AM
Cancer Med; 2020 Feb; 9(3):1033-1043. PubMed ID: 31850687
[TBL] [Abstract][Full Text] [Related]
3. Impact of different palliative systemic treatments on skeletal muscle mass in metastatic colorectal cancer patients.
Kurk SA; Peeters PHM; Dorresteijn B; de Jong PA; Jourdan M; Kuijf HJ; Punt CJA; Koopman M; May AM
J Cachexia Sarcopenia Muscle; 2018 Oct; 9(5):909-919. PubMed ID: 30144305
[TBL] [Abstract][Full Text] [Related]
4. Association between body composition, survival, and toxicity in advanced esophagogastric cancer patients receiving palliative chemotherapy.
Dijksterhuis WPM; Pruijt MJ; van der Woude SO; Klaassen R; Kurk SA; van Oijen MGH; van Laarhoven HWM
J Cachexia Sarcopenia Muscle; 2019 Feb; 10(1):199-206. PubMed ID: 30666831
[TBL] [Abstract][Full Text] [Related]
5. Sarcopenia supersedes subjective global assessment as a predictor of survival in colorectal cancer.
Vashi PG; Gorsuch K; Wan L; Hill D; Block C; Gupta D
PLoS One; 2019; 14(6):e0218761. PubMed ID: 31220163
[TBL] [Abstract][Full Text] [Related]
6. Trajectory of body mass and skeletal muscle indices and disease progression in metastatic colorectal cancer patients.
Kurk SA; Stellato RK; Peeters PHM; Dorresteijn B; Jourdan M; Oskam MJ; Punt CJA; Koopman M; May AM
Am J Clin Nutr; 2019 Dec; 110(6):1395-1403. PubMed ID: 31515555
[TBL] [Abstract][Full Text] [Related]
7. Women are predisposed to early dose-limiting toxicities during adjuvant CAPOX for colorectal cancer.
Nozawa H; Kawai K; Sasaki K; Murono K; Emoto S; Yokoyama Y; Abe S; Kishikawa J; Nagai Y; Sonoda H; Anzai H; Ozawa T; Ishihara S
Int J Clin Pract; 2021 Nov; 75(11):e14863. PubMed ID: 34516723
[TBL] [Abstract][Full Text] [Related]
8. Skeletal Muscle Measures as Predictors of Toxicity, Hospitalization, and Survival in Patients with Metastatic Breast Cancer Receiving Taxane-Based Chemotherapy.
Shachar SS; Deal AM; Weinberg M; Nyrop KA; Williams GR; Nishijima TF; Benbow JM; Muss HB
Clin Cancer Res; 2017 Feb; 23(3):658-665. PubMed ID: 27489287
[TBL] [Abstract][Full Text] [Related]
9. Randomized Phase II Trial of CapOX plus Bevacizumab and CapIRI plus Bevacizumab as First-Line Treatment for Japanese Patients with Metastatic Colorectal Cancer (CCOG-1201 Study).
Nakayama G; Mitsuma A; Sunagawa Y; Ishigure K; Yokoyama H; Matsui T; Nakayama H; Nakata K; Ishiyama A; Asada T; Umeda S; Ezaka K; Hattori N; Takami H; Kobayashi D; Tanaka C; Kanda M; Yamada S; Koike M; Fujiwara M; Fujii T; Murotani K; Ando Y; Kodera Y
Oncologist; 2018 Aug; 23(8):919-927. PubMed ID: 30049885
[TBL] [Abstract][Full Text] [Related]
10. Capecitabine plus bevacizumab versus capecitabine in maintenance treatment for untreated characterised KRAS exon 2 wild-type metastatic colorectal cancer: a retrospective analysis in Chinese postmenopausal women.
Su J; Lai J; Yang R; Xu B; Zhu Y; Zhao M; Yang C; Liang G
BMC Gastroenterol; 2019 Jan; 19(1):17. PubMed ID: 30683047
[TBL] [Abstract][Full Text] [Related]
11. Capecitabine Plus Oxaliplatin and Bevacizumab, Followed by Maintenance Treatment With Capecitabine and Bevacizumab for Patients Aged > 75 Years With Metastatic Colorectal Cancer.
Petrioli R; Francini E; Cherri S; Torre P; Fiaschi AI; Miano ST; Marrelli D; Rovello F; Francini G
Clin Colorectal Cancer; 2018 Dec; 17(4):e663-e669. PubMed ID: 30153975
[TBL] [Abstract][Full Text] [Related]
12. Sarcopenic obesity: A probable risk factor for dose limiting toxicity during neo-adjuvant chemotherapy in oesophageal cancer patients.
Anandavadivelan P; Brismar TB; Nilsson M; Johar AM; Martin L
Clin Nutr; 2016 Jun; 35(3):724-30. PubMed ID: 26065721
[TBL] [Abstract][Full Text] [Related]
13. Skeletal muscle loss during chemotherapy and its association with survival and systemic treatment toxicity in metastatic colorectal cancer: An AGEO prospective multicenter study.
Gallois C; Bourillon C; Auclin E; Artru P; Lièvre A; Lecomte T; Locher C; Marthey L; Faroux R; Pernot S; Barret M; Taieb J
Clin Res Hepatol Gastroenterol; 2021 Nov; 45(6):101603. PubMed ID: 33662782
[TBL] [Abstract][Full Text] [Related]
14. Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group.
Simkens LH; van Tinteren H; May A; ten Tije AJ; Creemers GJ; Loosveld OJ; de Jongh FE; Erdkamp FL; Erjavec Z; van der Torren AM; Tol J; Braun HJ; Nieboer P; van der Hoeven JJ; Haasjes JG; Jansen RL; Wals J; Cats A; Derleyn VA; Honkoop AH; Mol L; Punt CJ; Koopman M
Lancet; 2015 May; 385(9980):1843-52. PubMed ID: 25862517
[TBL] [Abstract][Full Text] [Related]
15. Regorafenib Is Associated With Increased Skeletal Muscle Loss Compared to TAS-102 in Metastatic Colorectal Cancer.
Huemer F; Schlintl V; Hecht S; Hackl H; Melchardt T; Rinnerthaler G; Greil R; Weiss L
Clin Colorectal Cancer; 2019 Jun; 18(2):159-166.e3. PubMed ID: 31060856
[TBL] [Abstract][Full Text] [Related]
16. Prevalence of sarcopenia in older patients with colorectal cancer.
Broughman JR; Williams GR; Deal AM; Yu H; Nyrop KA; Alston SM; Gordon BB; Sanoff HK; Muss HB
J Geriatr Oncol; 2015 Nov; 6(6):442-5. PubMed ID: 26365898
[TBL] [Abstract][Full Text] [Related]
17. Factors Contributing to Cancer-Related Muscle Wasting During First-Line Systemic Treatment for Metastatic Colorectal Cancer.
Derksen JWG; Kurk SA; Oskam MJ; Peeters PHM; Punt CJA; Koopman M; May AM
JNCI Cancer Spectr; 2019 Jun; 3(2):pkz014. PubMed ID: 31360897
[TBL] [Abstract][Full Text] [Related]
18. Cediranib plus FOLFOX/CAPOX versus placebo plus FOLFOX/CAPOX in patients with previously untreated metastatic colorectal cancer: a randomized, double-blind, phase III study (HORIZON II).
Hoff PM; Hochhaus A; Pestalozzi BC; Tebbutt NC; Li J; Kim TW; Koynov KD; Kurteva G; Pintér T; Cheng Y; van Eyll B; Pike L; Fielding A; Robertson JD; Saunders MP
J Clin Oncol; 2012 Oct; 30(29):3596-603. PubMed ID: 22965965
[TBL] [Abstract][Full Text] [Related]
19. Intermittent weekly high-dose capecitabine in combination with oxaliplatin: a phase I/II study in first-line treatment of patients with advanced colorectal cancer.
Scheithauer W; Kornek GV; Raderer M; Schüll B; Schmid K; Längle F; Huber H
Ann Oncol; 2002 Oct; 13(10):1583-9. PubMed ID: 12377646
[TBL] [Abstract][Full Text] [Related]
20. Relation between sarcopenia and dose-limiting toxicity in patients with metastatic colorectal cancer who received regorafenib.
Gökyer A; Küçükarda A; Köstek O; Hacıoğlu MB; Sunal BS; Demircan NC; Uzunoğlu S; Solak S; İşsever K; Çiçin I; Erdoğan B
Clin Transl Oncol; 2019 Nov; 21(11):1518-1523. PubMed ID: 30868388
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
